title: Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.
abstract: Cetuximab is a monoclonal antibody against epidermal growth factor receptor useful in the treatment of patients with Head and Neck Squamous Cell Carcinoma combined with radiotherapy or chemotherapy. Its pharmacokinetics are not influenced by hepatic status and there are no specific warnings concerning its indication in patients with impaired hepatic function. Patients with a previous liver transplant are at risk for hepatic toxicity and use immunosupressants to avoid rejection that can interact with other drugs. We present two cases of patients with a previous liver transplant in which cetuximab was administered to treat head and neck cancer.
authors.affiliation: a Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital JosepTrueta , Girona , Spain.
authors.forename: Francia
authors.initials: F
authors.lastname: Holguin
authors.affiliation: a Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital JosepTrueta , Girona , Spain.|b Descriptive Epidemiology, Genetics and Cancer Prevention Group , Biomedical Research Institute (IDIBGI) , Girona , Spain.
authors.forename: Jordi
authors.initials: J
authors.lastname: Rubió-Casadevall
authors.affiliation: c Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital Duran I Reynalds , L'Hospitalet de LLobregat, Barcelona , Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Saigi
authors.affiliation: d Deparment of Radiotherapy, Catalan Institute of Oncology , Hospital JosepTrueta , Girona , Spain.
authors.forename: Jordi
authors.initials: J
authors.lastname: Marruecos
authors.affiliation: c Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital Duran I Reynalds , L'Hospitalet de LLobregat, Barcelona , Spain.
authors.forename: Miren
authors.initials: M
authors.lastname: Taberna
authors.affiliation: e Deparment of Otorhinolaringology , Hospital Universitari JosepTrueta , Servei Català de la Salut, Girona , Spain.
authors.forename: Marc
authors.initials: M
authors.lastname: Tobed
authors.affiliation: f Deparment of Otorhinolaringology , Hospital Universitari de Bellvitge, University of Barcelona , Servei Català de la Salut, Barcelona , Spain.|g Medical Oncology Department , Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) , Hospitalet de LLobregat, Barcelona , Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Maños
authors.affiliation: c Deparment of Medical Oncology, Catalan Institute of Oncology , Hospital Duran I Reynalds , L'Hospitalet de LLobregat, Barcelona , Spain.|g Medical Oncology Department , Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) , Hospitalet de LLobregat, Barcelona , Spain.
authors.forename: Ricard
authors.initials: R
authors.lastname: Mesía
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D000068818:Cetuximab / Q000627:therapeutic use*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D016031:Liver Transplantation / Q000379:methods; D008297:Male; D008875:Middle Aged
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000068818:Cetuximab
keywords: Cetuximab; Head and neck cancer; Immunosuppressors; Liver transplant; Tacrolimus; mTOR inhibitors